The TRANSEVER registry—a 33-centre Indian prospective study—tracked 1,000 consecutive patients receiving the polymer-free everolimus-eluting ISAR SUMMIT stent during percutaneous coronary intervention. At 12 months, target-lesion failure occurred in just 15 patients (1.5%), definite or probable stent thrombosis in 8 (0.8%), and the broader patient-oriented composite endpoint in only 21 patients (2.1%). Critically, 89.8% of the cohort presented with acute coronary syndrome and 44.4% had diabetes—two factors traditionally associated with worse stent outcomes.
The results deserve attention because polymer-free drug-eluting stents represent a meaningful engineering evolution. Conventional durable-polymer platforms can trigger persistent inflammatory responses and delayed endothelial healing, which drive late and very late stent thrombosis—a rare but catastrophic complication. By eliminating the polymer carrier, devices like the ISAR SUMMIT aim to reduce this chronic irritation while preserving antirestenotic drug delivery. A 0.8% thrombosis rate in a predominantly ACS population is competitive with benchmark contemporary drug-eluting stent trials. However, context matters: this is a single-arm registry without a randomized comparator, making it impossible to attribute outcomes causally to the polymer-free design rather than operator skill, patient selection nuances, or adjunct pharmacotherapy protocols. One-year follow-up also cannot capture very late events, which are the key theoretical advantage of polymer-free platforms. As a preprint not yet peer-reviewed, methodology and data integrity require independent scrutiny before clinical guidance shifts. Confirmatory, with incremental rather than paradigm-shifting implications.